Explore

Rapid ReadRapid Read
Biohub Secures $1.8 Billion for 'Virtual Biology' Initiative to Accelerate Scientific Discovery

Biohub Secures $1.8 Billion for 'Virtual Biology' Initiative to Accelerate Scientific Discovery

Biohub, a non-profit research organization founded by Meta CEO Mark Zuckerberg and Priscilla Chan, has secured $1.8 billion in funding for its 'Virtual Biology' initiative. This AI-powered open-source platform aims to create a 'world model' of biology to serve as a discovery engine for protein structure prediction, design, and broader biological insights. The substantial investment comes from a consortium of major entities, including the U.S. Department of Energy (DOE), the National Institutes of Health (NIH), Meta, Google DeepMind, and Isomorphic Labs. The funding is not solely cash; a significant portion comprises data, computational resources, and advanced measurement technology. Launched in April with initial funding of $500 million, the initiative seeks to enable scientists to conduct experiments digitally, thereby accelerating scientific discovery and understanding of diseases.
Rapid ReadRapid Read
U.S. Government and Tech Giants Invest $1.8 Billion in AI for Biological Research

U.S. Government and Tech Giants Invest $1.8 Billion in AI for Biological Research

The U.S. government, in collaboration with technology companies Meta Platforms and Alphabet, is partnering with the nonprofit Biohub to create extensive open datasets for training advanced AI models in biological research. This initiative has garnered a total investment of $1.8 billion. Meta Platforms, Google DeepMind, and drug discovery startup Isomorphic Labs are contributing $300 million. Concurrently, the Department of Energy is committing over $500 million across five years for laboratory measurement, modeling, and computation. The National Institutes of Health will coordinate existing repositories and open datasets, established with over $500 million in previous federal grants, which Biohub will standardize for AI model training. These new pledges build upon a prior $500 million investment made by Biohub in April. The project, known as the Virtual Biology Initiative, aims to observe and measure cellular responses to environmental changes across a vast range of conditions, far exceeding previous studi...
Rapid ReadRapid Read
Diethyl Fumarate Shows Promise Against Drug-Tolerant Tuberculosis Persisters

Diethyl Fumarate Shows Promise Against Drug-Tolerant Tuberculosis Persisters

A study published in Frontiers in Cellular and Infection Microbiology indicates that diethyl fumarate (DEF) exhibits potent activity against differentially culturable Mycobacterium tuberculosis (Mtb) persisters. These persisters are drug-tolerant forms of Mtb that contribute to prolonged tuberculosis treatment and disease relapse. The research developed a workflow to evaluate drug candidates against these persisters, validating it with dimethyl fumarate (DMF) derivatives. While DMF and DEF inhibited Mtb growth, ethyl-3-benzoylacrylate (EBL) and methyl-trans-4-oxo-2-pentenoate (MTOP) demonstrated bactericidal activity against both Mtb and Mycobacterium abscessus (Mabs). The study found that DMF and DEF effectively eliminated DC Mtb within infected macrophages, suggesting their anti-persister activity is mediated through modulating the host immune response, particularly by inhibiting nitric oxide (NO) production, rather than solely through direct action on Mtb. This dual anti-inflammatory and anti-mycobacter...
Rapid ReadRapid Read
AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

Artificial Intelligence (AI)-enabled tools are fundamentally changing how clinical trial feasibility is conducted, shifting it from a retrospective validation step to an ongoing, iterative part of protocol development. Traditionally, feasibility studies were performed late in the process, after a protocol was largely finalized, leading to delays and costly amendments if assumptions about cohort sizes, outcome rates, or eligibility criteria proved incorrect. AI tools, such as those offered by TriNetX, now allow study teams to evaluate assumptions against real-world data (RWD) continuously as criteria are being set. This is made possible by natural language interfaces that enable users to enter eligibility criteria in plain language, which the system then translates into clinical code sets to generate patient counts instantly. For example, adjusting a single BMI exclusion criterion in a type 2 diabetes query can change the cohort size by thousands of patients in real-time, providing immediate visual feedback...
TrendlineTrendline
Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina

Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina

Obatala Sciences Establishes First East Coast Operation in Charleston County, South Carolina
Rapid ReadRapid Read
National Cancer Institute Renews UNC Biostatistics Grant for Genomics and Cancer Research

National Cancer Institute Renews UNC Biostatistics Grant for Genomics and Cancer Research

The National Cancer Institute (NCI) has renewed a long-standing training grant for the Biostatistics for Research in Genomics and Cancer program at the UNC Gillings School of Global Public Health. This program, continuously funded by NCI since 2004, is led by Alumni Distinguished Professor Joseph G. Ibrahim, PhD, and Associate Professor Naim Rashid, PhD. It supports five predoctoral trainees at a time, preparing doctoral students for careers at the intersection of statistical methodology, genomics, and cancer research. The program emphasizes rigorous methodological training combined with immersion in cancer and genomics research, allowing trainees to collaborate with cancer biologists, clinicians, and genomic scientists. This interdisciplinary approach addresses research questions that require both new statistical methods and a deep understanding of the underlying science. The curriculum has evolved to include high-dimensional modeling, multimodal data integration, computation, machine learning, and artifi...
ReutersReuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom

Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom

By Manya Saini and Niket Nishant Oct 8 (Reuters) - Nvidia-backed Iambic Therapeutics, which uses AI to develop drugs, is aiming to raise up to $159.4 million in its US IPO, as the biotech sector emerges as a bright spot in an otherwise lackluster market.
TrendlineTrendline
Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development

Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development

Rockwell Automation and Industry Leaders Form Digital CMC Consortium to Accelerate Pharmaceutical Development
TrendlineTrendline
Biological Crop Protection Gains Traction Amidst Regulatory and Consumer Shifts

Biological Crop Protection Gains Traction Amidst Regulatory and Consumer Shifts

Biological Crop Protection Gains Traction Amidst Regulatory and Consumer Shifts
TrendlineTrendline
ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance
Rapid ReadRapid Read
AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...
TrendlineTrendline
Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension

Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension

Gilead Sciences Expands AI-Enabled DevOps Capabilities with Cognizant Partnership Extension